Melissa Fischer received her PhD in Biochemistry from Vanderbilt University in 2011, and joined the Savona Lab in 2015. Her graduate work focused on the role of Myeloid Translocation Gene 16 (MTG16 also known as ETO2), that is disrupted in Acute Myeloid Leukemia (AML) by the translocation t(16;21).
In the Savona lab, she studies hematopoiesis and tests novel drug therapies for myeloid malignancies. She has optimized high throughput methods to screen malignant myeloid cells for response to inhibitors, and is currently spearheading the development of three-dimensional stromal models to study myelodysplastic cells ex vivo. She is interested in applying her expertise in hematopoietic biology to the development of preclinical assays to test novel drug therapies for myeloid malignancies.